Anthony Letai Selected Research

Neoplasms (Cancer)

10/2022	Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.
1/2022	Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens.
1/2022	Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis.
1/2022	IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.
1/2022	Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
12/2021	Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
11/2021	In Conversation with Tony Letai.
10/2021	Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening.
1/2021	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
1/2021	Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony Letai Research Topics

Disease

74	Neoplasms (Cancer) 10/2022 - 09/2002
15	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2022 - 10/2012
13	Leukemia 01/2022 - 11/2009
9	Breast Neoplasms (Breast Cancer) 01/2021 - 10/2008
9	Lymphoma (Lymphomas) 01/2021 - 04/2003
8	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 08/2012
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 01/2007
5	Multiple Myeloma 06/2022 - 11/2005
5	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2017
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 02/2008
4	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 04/2013
4	Lung Neoplasms (Lung Cancer) 01/2018 - 12/2007
4	Carcinogenesis 05/2014 - 01/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2012
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2020 - 08/2012
3	B-Cell Leukemia (Leukemia, B Cell) 10/2016 - 01/2007
2	Carcinoma (Carcinomatosis) 10/2021 - 11/2016
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2021 - 09/2015
2	Triple Negative Breast Neoplasms 01/2021 - 11/2020
2	Infections 01/2020 - 01/2018
2	Thrombocytopenia (Thrombopenia) 01/2020 - 08/2013
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019 - 06/2005
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021
1	Aneuploidy (Aneuploid) 12/2020
1	Febrile Neutropenia 01/2020
1	Neutropenia 01/2020
1	Nausea 01/2020
1	Ovarian Neoplasms (Ovarian Cancer) 11/2019
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2019
1	Wilms Tumor (Wilm's Tumor) 01/2019
1	Esophageal Neoplasms (Esophageal Cancer) 06/2018
1	Sepsis (Septicemia) 01/2018
1	Respiratory Insufficiency (Respiratory Failure) 01/2018

Drug/Important Bio-Agent (IBA)

39	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2003
26	venetoclaxIBA 04/2022 - 01/2013
8	Pharmaceutical PreparationsIBA 11/2021 - 02/2015
6	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2012
6	Peptides (Polypeptides)IBA 01/2018 - 09/2002
6	ABT-737IBA 08/2012 - 06/2005
5	navitoclaxIBA 01/2021 - 08/2013
5	Apoptosis Regulatory ProteinsIBA 01/2021 - 11/2009
4	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 01/2019
4	Biological ProductsIBA 12/2016 - 10/2012
3	S63845IBA 01/2021 - 12/2020
3	Estrogen ReceptorsIBA 01/2021 - 01/2013
3	Phosphotransferases (Kinase)IBA 01/2018 - 12/2017
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 12/2007
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2021
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 06/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 01/2021
2	ChromatinIBA 01/2022 - 01/2021
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 10/2020
2	Drug CombinationsIBA 01/2021 - 01/2021
2	Decitabine FDA Link 01/2021 - 01/2019
2	ErbB Receptors (EGF Receptor)IBA 11/2020 - 12/2007
2	taxaneIBA 11/2019 - 10/2008
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2019 - 06/2014
2	Small Interfering RNA (siRNA)IBA 01/2017 - 05/2014
2	Antineoplastic Agents (Antineoplastics)IBA 05/2014 - 10/2008
1	antineoplaston A10 (A 10)IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	tofacitinibIBA 01/2022
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	A-1331852IBA 01/2021
1	AlpelisibIBA 01/2021
1	ipatasertibIBA 01/2021
1	Etoposide (VP 16)FDA LinkGeneric 01/2021
1	ABT-414IBA 11/2020
1	Immunoconjugates (Immunoconjugate)IBA 11/2020
1	tazemetostatIBA 10/2020
1	Histone MethyltransferasesIBA 10/2020
1	Lysine (L-Lysine)FDA Link 10/2020
1	Ligases (Synthetase)IBA 11/2019
1	UbiquitinIBA 11/2019
1	tagraxofuspIBA 11/2019
1	PlatinumIBA 11/2019
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 11/2019
1	Thalidomide (Thalomid)FDA Link 11/2019
1	Vincristine (Oncovin)FDA LinkGeneric 01/2019
1	ProteomeIBA 01/2019
1	copanlisibIBA 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	ProhibitinsIBA 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	RNA Splicing FactorsIBA 10/2018
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	Oxidoreductases (Dehydrogenase)IBA 01/2018
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 01/2018
1	Coenzyme A (CoA)IBA 01/2018

Therapy/Procedure

49	Therapeutics 10/2022 - 09/2002
26	Drug Therapy (Chemotherapy) 01/2021 - 01/2007
9	Precision Medicine 10/2022 - 12/2015
2	Immunotherapy 01/2022 - 01/2021
2	Aftercare (After-Treatment) 01/2020 - 08/2012
1	Combination Drug Therapy (Combination Chemotherapy) 11/2019
1	Neoadjuvant Therapy 06/2018
1	Esophagectomy 06/2018